Medicine & Life Sciences
Child
5%
Cost-Benefit Analysis
11%
Half-Life
11%
Immunization
10%
Income
10%
Infant Mortality
14%
Licensure
13%
Monoclonal Antibodies
37%
Morbidity
7%
Mortality
6%
Neutralizing Antibodies
12%
Parturition
8%
Population
5%
Referral and Consultation
47%
Respiratory Syncytial Virus Vaccines
100%
Respiratory Syncytial Viruses
75%
Vaccines
19%
Virus Diseases
9%
Agriculture & Biology
cost effectiveness
9%
death
7%
disease control
8%
dosage
4%
efficacy testing
11%
half life
8%
immunization
9%
income
7%
infant mortality
12%
monoclonal antibodies
32%
morbidity
9%
neutralizing antibodies
10%
pregnant women
11%
product development
10%
Respiratory syncytial virus
96%
respiratory tract diseases
9%
vaccine development
79%
vaccines
31%
Social Sciences
candidacy
16%
cause
12%
costs
12%
death
15%
expert
13%
Group
6%
income
14%
infant
35%
low income
16%
morbidity
21%
mortality
36%
pregnant women
23%
prophylaxis
28%
WHO
60%